Filters
Technology
Platform
Homo sapiens
12 Downloadable Samples
Affymetrix HT Human Genome U133A Array (hthgu133a)
Description
breast cancer. Combined IGF and estrogen-targeted therapy may improve the benefit of hormonal therapy alone. We employed a postmenopausal model of estrogen-dependent breast cancer in vitro and in vivo using the aromatase-expressing MCF-7/AC-1cells. Using this model, we investigated the anti-tumor effects of the dual IGF-1R/InsR tyrosine kinase inhibitor, BMS-754807 alone and in combination with letrozole or tamoxifen in vivo.
Publication Title
No associated publication
Sample Metadata Fields
Specimen part, Treatment
View Samples- Homo sapiens
- 6 Downloadable Samples
- Affymetrix Human Genome U133A Array (hgu133a)
Description
Transcriptional profiling for global characterization of gene expression alterations that resulted from treatment of melanoma cells with siRNA specifically targeting NRASQ61R
Publication Title
Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.
Sample Metadata Fields
No sample metadata fields
View Samples- Homo sapiens
- 278 Downloadable Samples
- Affymetrix Human Genome U133A 2.0 Array (hgu133a2)
Description
A randomized, open-label, multicenter, phase II trial (NCT00455533) enrolled previously untreated women with histologically-confirmed primary invasive breast adenocarcinoma (T23, N03, M0, tumor size 2.0 cm), regardless of hormone receptor or HER2 expression status. Patients received sequential neoadjuvant therapy starting with 4 cycles of AC (doxorubicin 60 mg/m2 intravenously and cyclophosphamide 600 mg/m2 intravenously) given every 3 weeks, followed by 1:1 randomization to either ixabepilone (40 mg/m2 3-hour infusion) every 3 weeks for 4 cycles, or paclitaxel (80 mg/m2 1-hour infusion) weekly for 12 weeks.
Publication Title
Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
Sample Metadata Fields
Sex, Age
View Samples
GSE110169- Homo sapiens
- 243 Downloadable Samples
- Affymetrix Human Genome U219 Array (hgu219)
Description
The goal of this study is to define the molecular signatures of SLE and RA patients.
Publication Title
No associated publication
Sample Metadata Fields
Sex, Disease
View Samples GSE110174- Homo sapiens
- 153 Downloadable Samples
- Affymetrix HT HG-U133+ PM Array Plate (hthgu133pluspm)
Description
The goal of this study is to define the molecular signatures of SLE patients at baseline in BMS IM101042 trial. IM101042 (NCT00119678) is a phase IIb, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept vs placebo on a background of oral glucocorticosteroids in the treatment of subjects with systemic lupus erythematosus and the prevention of subsequent lupus flares, sponsored by Bristol-Myers Squibb.
Publication Title
No associated publication
Sample Metadata Fields
No sample metadata fields
View Samples GSE110160- Homo sapiens
- 152 Downloadable Samples
- Affymetrix HT Human Genome U133A Array (hthgu133a)
Description
The goal of this study is to define the molecular signatures of prednisolone in vivo. IM124001 (NCT03196557) is an experimental medicine study to assess the pharmacodynamics following administration of multiple doses of prednisolone to healthy male subjects, sponsored by Bristol-Myers Squibb.
Publication Title
No associated publication
Sample Metadata Fields
Time
View Samples- Homo sapiens
- 111 Downloadable Samples
- Affymetrix HT Human Genome U133A Array (hthgu133a)
Description
Cell Line: This experiment was designed to measure the transcriptional responses to four kinase inhibitors across a five-logarithm dose range. The A549 human lung cancer cell line was treated with dasatinib, imatinib or nilotinib (4 hours and 20 hours) or PD0325901 (4 hours). Treatments used a 12-point dose range (30 uM with 3-fold dilutions down to 0.17 nM; 0.5% DMSO vehicle for all treatments). Experimental design prevented row or column handling effects being confounded with dose effect.
Publication Title
Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities.
Sample Metadata Fields
Disease, Cell line, Compound, Time
View Samples- Homo sapiens
- 58 Downloadable Samples
- Affymetrix HT Human Genome U133A Array (hthgu133a)
Description
The goal of these studies is to identify genes that are regulated by glucocorticoids in human peripheral blood mononuclear cells in vitro.
Publication Title
No associated publication
Sample Metadata Fields
Treatment, Subject
View Samples- Homo sapiens
- 45 Downloadable Samples
- Affymetrix HT Human Genome U133A Array (hthgu133a), Affymetrix Human Genome U133A 2.0 Array (hgu133a2)
Description
To investigate an unknown mechanism of cytotoxicity, A549 human lung-cancer cells were treated with compounds from a series of inhibitors developed against the human LIM kinases LIMK1 and LIMK2. Compounds 1 and 2 inhibit LIM kinase activity in vitro and affect cell proliferation and survival in vivo. Compounds 3 and 4 inhibit LIM kinases but do not affect cell survival or proliferation. Compounds 5 and 6 affect proliferation and survival but do not inhibit LIM kinases. Nocodazole was included as a comparator because the compounds were known to affect microtubule stability. A treatment of 7 hours was used to examine events prior to apoptosis, while the dose levels captured both cytotoxicity and inhibition of LIMKs (Compounds 1 and 2), LIMK inhibition alone ( Compounds 3 and 4) or cytotoxicity alone (Compounds 5, 6, and Nocodazole).
Publication Title
Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.
Sample Metadata Fields
Cell line, Subject, Compound
View Samples GSE110161- Homo sapiens
- 39 Downloadable Samples
- Affymetrix HT Human Genome U133A Array (hthgu133a)
Description
The goal of this study is to define the molecular signatures of prednisolone and BMS-791826 in normal healthy volunteers. IM125001 (NCT03198013) is a phase I, placebo-controlled, double-blind, ascending single and multiple oral dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of bms-791826 and to assess its marker specific pharmacodynamics in relation to prednisolone in healthy males, sponsored by Bristol-Myers Squibb.
Publication Title
No associated publication
Sample Metadata Fields
No sample metadata fields
View Samples